6709 fundamentals
An in-depth look to ADVAGENE BIOPHARMA CO LTD operating, investing, and financing activities
6709 free cash flow for H2 24 is -43.28 M TWD. For 2024, 6709 free cash flow was -71 M TWD and operating cash flow was -70.53 M TWD.
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: TWD
TTM